Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EBITDA (2022 - 2025)

Historic EBITDA for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to -$2.2 million.

  • bioAffinity Technologies' EBITDA fell 1628.51% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.2 million, marking a year-over-year decrease of 2657.63%. This contributed to the annual value of -$8.8 million for FY2024, which is 1357.79% down from last year.
  • bioAffinity Technologies' EBITDA amounted to -$2.2 million in Q3 2025, which was down 1628.51% from -$2.5 million recorded in Q2 2025.
  • bioAffinity Technologies' 5-year EBITDA high stood at -$684119.0 for Q2 2022, and its period low was -$2.9 million during Q4 2024.
  • Moreover, its 4-year median value for EBITDA was -$1.9 million (2024), whereas its average is -$1.9 million.
  • As far as peak fluctuations go, bioAffinity Technologies' EBITDA tumbled by 15687.78% in 2023, and later soared by 1404.89% in 2024.
  • bioAffinity Technologies' EBITDA (Quarter) stood at -$1.6 million in 2022, then tumbled by 34.62% to -$2.2 million in 2023, then tumbled by 33.44% to -$2.9 million in 2024, then rose by 22.57% to -$2.2 million in 2025.
  • Its EBITDA stands at -$2.2 million for Q3 2025, versus -$2.5 million for Q2 2025 and -$2.6 million for Q1 2025.